The FINANCIAL -- Bayer
HealthCare announced the 2012 recipients of the Bayer Hemophilia
Awards Program.
As Bayer AG reported, this year, the company awards a total of approximately 2.3 million USD in funding to 15 recipients in nine countries. BHAP is the largest program of its kind in hemophilia, funding innovative research and educational initiatives around the world. As such, BHAP is a key program in Hemophilia Solutions, Bayer’s program of commitment to research, treatment and education in hemophilia.
The 2012 announcement is especially meaningful, as it marks the 10th anniversary of BHAP and its resulting contributions to the global hemophilia community. Since its founding in 2002, BHAP has awarded more than 200 grants, totaling more than 24 million USD, to researchers and caregivers from 29 countries around the world. BHAP support has resulted in more than 360 scientific abstracts, publications and presentations by awardees.
“The scientists and caregivers we honor today are performing the research needed to develop, for example, improved hemophilia therapies,” said Prasad Mathew, Vice President, Global Medical Affairs Hematology, Bayer HealthCare. “They are laying the groundwork for greater understanding of many aspects of hemophilia, and I look forward to seeing the results of their valuable work in the future.”
BHAP awardees are selected by a global panel of distinguished hemophilia clinicians, researchers and caregivers. Awards are given in four categories; Special Project, Early Career Investigator, Fellowship Project and Caregiver.“Those receiving the BHAP award this year are an extraordinary group of researchers and caregivers. While the selection process is never easy, we are consistently impressed by the quality of the research. We are confident that this year’s winners will make meaningful advances to hemophilia research,” said Prof. Johannes Oldenburg, chairman of the BHAP Grants, Review and Awards Committee and Head of the Institute of Experimental Haematology and Transfusion Medicine at University Clinic Bonn.
BHAP is one example of Bayer’s commitment to expanding the scientific and clinical knowledge that improves patient care. BHAP research priorities include prophylaxis, impact of advancing age on hemophilia patients, treatment innovations, and the mechanism of action of clotting factor concentrates.
The 2012 BHAP award recipients were announced at the World Federation of Hemophilia (WFH) Congress in Paris.
Related Stories
